Mucin 1-specific B cell immune responses and their impact on overall survival in breast cancer patients

OncoImmunology

Volumn 5, Issue 1, 2016, Pages

  Fremd, Carlo ^a   Stefanovic, Stefan ^a   Beckhove, Philipp ^b   Pritsch, Maria ^b   Lim, Hendry ^b   Wallwiener, Markus ^a   Heil, Joerg ^a   Golatta, Michael ^a   Rom, Joachim ^a   Sohn, Christof ^a   Schneeweiss, Andreas ^a   Schuetz, Florian ^a   Domschke, Christoph ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

ADCC; B cells; Breast cancer; Immunoglobulin G; MUC1 specific antibodies; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN M; KI 67 ANTIGEN; MUCIN 1;

ADULT; ANTIBODY SPECIFICITY; ARTICLE; B LYMPHOCYTE; BLOOD ANALYSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER STAGING; CANCER SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE AMPLIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MIDDLE AGED; PARTIAL MASTECTOMY; PROPORTIONAL HAZARDS MODEL;

EID: 84954407806     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1057387     Document Type: Article

References (38)

1. Fremd C, Schuetz F, Sohn C, Beckhove P, Domschke C. B cell-regulated immune responses in tumor models and cancer patients. Oncoimmunology 2013; 2: e25443; PMID:24073382; http://dx. doi. org/10. 4161/ onci. 25443
2. Affara NI, Ruffell B, Medler TR, Gunderson AJ, Johansson M, Bornstein S, Bergsland E, Steinhoff M, Li Y, Gong Q et al. B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas. Cancer Cell 2014; 25:809-21; PMID:24909985; http://dx. doi. org/10. 1016/j. ccr. 2014. 04. 026
3. Gunderson AJ, Coussens LM. B cells and their mediators as targets for therapy in solid tumors. Exp Cell Res 2013; 319:1644-9; PMID:23499742; http://dx. doi. org/10. 1016/j. yexcr. 2013. 03. 005
4. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol 2001; 19:275-90; PMID:11244038; http:// dx. doi. org/10. 1146/annurev. immunol. 19. 1. 275
5. Ammirante M, Luo JL, Grivennikov S, Nedospasov S, Karin M. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 2010; 464:302-5; PMID:20220849; http://dx. doi. org/10. 1038/nature 08782
6. Domschke C, Schuetz F, Ge Y, Seibel T, Falk C, Brors B, Vlodavsky I, Sommerfeldt N, Sinn HP, Kühnle MC et al. Intratumoral cytokines and tumor cell biology determine spontaneous breast cancer-specific immune responses and their correlation to prognosis. Cancer Res 2009; 69:8420-8; PMID:19843863; http://dx. doi. org/10. 1158/0008-5472. CAN-09-1627
7. Domschke C, Schuetz F, Sommerfeldt N, Rom J, Scharf A, Sohn C, Schneeweiss A, Beckhove P. Effects of distant metastasis and peripheral CA 15-3 on the induction of spontaneous T cell responses in breast cancer patients. Cancer Immunol Immunother 2010; 59:479-86; PMID:19957084; http://dx. doi. org/ 10. 1007/s00262-009-0801-9
8. Karagiannis P, Gilbert AE, Josephs DH, Ali N, Dodev T, Saul L, Correa I, Roberts L, Beddowes E, Koers A et al. IgG4 subclass antibodies impair antitumor immunity in melanoma. J Clin Invest 2013; 123:1457-74; PMID:23454746; http://dx. doi. org/10. 1172/ JCI65579
9. von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P, Snijdewint FG, Kok A, Van Kamp GJ, Paul MA, Van Diest PJ, Meijer S, Hilgers J. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelialmucin. J Clin Oncol 2000; 18:574-83;PMID:10653872
10. Gourevitch MM, von Mensdorff-Pouilly S, Litvinov SV, Kenemans P, van Kamp GJ, Verstraeten AA, Hilgers J. Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients. Br J Cancer 1995; 72:934-8; PMID:7547243; http://dx. doi. org/10. 1038/bjc. 1995. 436
11. Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer 2009; 9:874-85; PMID:19935676; http://dx. doi. org/10. 1038/nrc2761
12. Patton S. MUC1 and MUC-X, epithelial mucins of breast and milk. Adv Exp Med Biol 2001; 501:35-45; PMID:11787701
13. Finn OJ, Gantt KR, Lepisto AJ, Pejawar-Gaddy S, Xue J, Beatty PL. Importance of MUC1 and spontaneous mouse tumor models for understanding the immunobiology of human adenocarcinomas. Immunol Res 2011; 50:261-8; PMID:21717081; http://dx. doi. org/ 10. 1007/s12026-011-8214-1
14. Taylor-Papadimitriou J, Burchell JM, Plunkett T, Graham R, Correa I, Miles D, Smith M. MUC1 and the immunobiology of cancer. J Mammary Gland Biol Neoplasia 2002; 7:209-21; PMID:12463741; http:// dx. doi. org/10. 1023/A:1020360121451
15. Von Mensdorff-Pouilly S, Moreno M, Verheijen RH. Natural and induced humoral responses to MUC1. Cancers (Basel) 2011; 3:3073-103; PMID:24212946; http://dx. doi. org/10. 3390/cancers3033073
16. Richards ER, Devine PL, Quin RJ, Fontenot JD, Ward BG, McGuckin MA. Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women. Cancer Immunol Immunother 1998; 46:245-52; PMID:9690452; http://dx. doi. org/10. 1007/s002620050484
17. Cramer DW, Titus-Ernstoff L, McKolanis JR, Welch WR, Vitonis AF, Berkowitz RS, Finn OJ. Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005; 14:1125-31; PMID:15894662; http://dx. doi. org/ 10. 1158/1055-9965. EPI-05-0035
18. Terry KL, Titus-Ernstoff L, McKolanis JR, Welch WR, Finn OJ, Cramer DW. Incessant ovulation, mucin 1 immunity, and risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 2007; 16:30-5; PMID:17220329; http://dx. doi. org/10. 1158/1055-9965. EPI-06-0688
19. Cramer DW, Vitonis AF, Pinheiro SP, McKolanis JR, Fichorova RN, Brown KE, Hatchette TF, Finn OJ. Mumps and ovarian cancer: modern interpretation of an historic association. Cancer Causes Control 2010; 21:1193-1201; PMID:20559706; http://dx. doi. org/ 10. 1007/s10552-010-9546-1
20. Pinheiro SP, Hankinson SE, Tworoger SS, Rosner BA, McKolanis JR, Finn OJ, Cramer DW. Anti-MUC1 antibodies and ovarian cancer risk: prospective data from the Nurses' Health Studies. Cancer Epidemiol Biomarkers Prev 2010;19:1595-1601; PMID:20501761; http://dx. doi. org/10. 1158/1055-9965. EPI-10-0068
21. Hermsen BB, Verheijen RH, Menko FH, Gille JJ, van Uffelen K, Blankenstein MA, Meijer S, van Diest PJ, Kenemans P, von Mensdorff-Pouilly S. Humoral immune responses to MUC1 in women with a BRCA1 or BRCA2 mutation. Eur J Cancer 2007; 43:1556-63; PMID:17532207; http://dx. doi. org/10. 1016/j. ejca. 2007. 04. 007
22. Lavrsen K, Madsen CB, Rasch MG, Woetmann A, Odum N, Mandel U, Clausen H, Pedersen AE, Wandall HH. Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity. Glycoconj J 2013; 30:227-36; PMID:22878593; http://dx. doi. org/10. 1007/s10719-012-9437-7
23. Croce MV, Isla-Larrain MT, Price MR, Segal-Eiras A. Detection of circulating mammary mucin (Muc1) and MUC1 immune complexes (Muc1-CIC) in healthy women. Int J Biol Markers 2001; 16:112-20; PMID:11471893
24. Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 2004; 4:45-60; PMID:14681689; http://dx. doi. org/10. 1038/nrc1251
25. Karsten U, von Mensdorff-Pouilly S, Goletz S. What makes MUC1 a tumor antigen? Tumour Biol 2005; 26:217-20; PMID:16006776; http://dx. doi. org/ 10. 1159/000086956
26. Agrawal B, Krantz MJ, Reddish MA, Longenecker BM. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat Med 1998; 4:43-9; PMID:9427605; http://dx. doi. org/ 10. 1038/nm0198-043
27. Zhang K, Sikut R, Hansson GC. A MUC1 mucin secreted from a colon carcinoma cell line inhibits target cell lysis by natural killer cells. Cell Immunol 1997; 176:158-65; PMID:9073389; http://dx. doi. org/ 10. 1006/cimm. 1997. 1085
28. Petrarca C, Casalino B, von Mensdorff-Pouilly S, Rughetti A, Rahimi H, Scambia G, Hilgers J, Frati L, Nuti M. Isolation of MUC1-primed B lymphocytes from tumour-draining lymph nodes by immunomagnetic beads. Cancer Immunol Immunother 1999; 47:272-7; PMID:10022471; http://dx. doi. org/ 10. 1007/s002620050531
29. von Mensdorff-Pouilly S, Petrakou E, Kenemans P, van Uffelen K, Verstraeten AA, Snijdewint FG, van Kamp GJ, Schol DJ, Reis CA, Price MR et al. Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-acetylgalactosamine (GalNAc) peptides. Int J Cancer 2000; 86:702-12; PMID:10797294; http://dx. doi. org/10. 1002/(SICI) 1097-0215(20000601)86:5%3c702::AIDIJC16% 3e3. 0. CO;2-1
30. Karagiannis P, Gilbert AE, Nestle FO, Karagiannis SN. IgG4 antibodies and cancer-associated inflammation: insights into a novel mechanism of immune escape. Oncoimmunology 2013; 2:e24889; PMID:24073371; http://dx. doi. org/10. 4161/onci. 24889
31. Pandey JP, Nietert PJ, Klaamas K, Kurtenkov O. A genetic variant of immunoglobulin gamma2 is strongly associated with immunity to mucin 1 in patients with breast cancer. Cancer Immunol Immunother 2009; 58:2025-9; PMID:19365631; http://dx. doi. org/ 10. 1007/s00262-009-0709-4
32. Ehrenstein MR, O'Keefe TL, Davies SL, Neuberger MS. Targeted gene disruption reveals a role for natural secretory IgM in the maturation of the primary immune response. Proc Natl Acad Sci U S A 1998; 95:10089-93; PMID:9707605; http://dx. doi. org/ 10. 1073/pnas. 95. 17. 10089
33. Chapman C, Murray A, Chakrabarti J, Thorpe A, Woolston C, Sahin U, Barnes A, Robertson J. Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol 2007; 18:868-73; PMID:17347129; http://dx. doi. org/10. 1093/annonc/ mdm007
34. Piura E, Piura B. Autoantibodies to tailor-made panels of tumor-associated antigens in breast carcinoma. Journal of Oncol 2011; 2011:982425; PMID:21423545; http://dx. doi. org/10. 1155/2011/982425
35. Evans RL, Pottala JV, Egland KA. Classifying patients for breast cancer by detection of autoantibodies against a panel of conformation-carrying antigens. Cancer Prev Res (Phila) 2014; 7:545-55; PMID:24641868; http:// dx. doi. org/10. 1158/1940-6207. CAPR-13-0416
36. Stefanovic S, Schuetz F, Sohn C, Beckhove P, Domschke C. Adoptive immunotherapy of metastatic breast cancer: present and future. Cancer Metastasis Rev 2014; 33:309-20; PMID:24337953; http://dx. doi. org/10. 1007/s10555-013-9452-6
37. Remmele W, Stegner HE. [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ERICA) in breast cancer tissue]. Pathologe 1987; 8:138-40; PMID:3303008
38. Ignatiadis M, Sotiriou C. Luminal breast cancer: from biology to treatment. Nat Rev Clin Oncol 2013; 10:494-506; PMID:23881035; http://dx. doi. org/ 10. 1038/nrclinonc. 2013. 124